Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of TNG348 Single Agent and in Combination With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or Other HRD+ Solid Tumors

NCT06065059 is registered in ClinicalTrials.gov with Tango Therapeutics, Inc. as lead sponsor.

NCT NCT06065059
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06065059 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of TNG348 Single Agent and in Combination With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or Other HRD+ Solid Tumors
Lead sponsor
Tango Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
December 8, 2023
Completion date
May 22, 2024
Enrollment
7 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

brca-associated breast carcinoma, brca-mutated ovarian carcinoma, brca1 mutation, breast cancer, hrd positive advanced ovarian cancer, ovarian cancer, pancreas cancer, prostate cancer